摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(Z)-ethyl 2-[2-(2,4-dichlorophenyl)hydrazono]-4-(4-chlorophenyl)-3-methyl-4-oxobutanoate | 434952-87-1

中文名称
——
中文别名
——
英文名称
(Z)-ethyl 2-[2-(2,4-dichlorophenyl)hydrazono]-4-(4-chlorophenyl)-3-methyl-4-oxobutanoate
英文别名
ethyl (2Z)-4-(4-chlorophenyl)-2-[(2,4-dichlorophenyl)hydrazinylidene]-3-methyl-4-oxobutanoate
(Z)-ethyl 2-[2-(2,4-dichlorophenyl)hydrazono]-4-(4-chlorophenyl)-3-methyl-4-oxobutanoate化学式
CAS
434952-87-1
化学式
C19H17Cl3N2O3
mdl
——
分子量
427.715
InChiKey
ZABCQXIFTGVHQM-ULJHMMPZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    536.3±60.0 °C(Predicted)
  • 密度:
    1.34±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    7
  • 重原子数:
    27
  • 可旋转键数:
    8
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.21
  • 拓扑面积:
    67.8
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • ‘One-pot’ synthesis of 4-substituted 1,5-diaryl-1H-pyrazole-3-carboxylates via lithium tert-butoxide-mediated sterically hindered Claisen condensation and Knorr reaction
    作者:Jian-An Jiang、Wei-Bin Huang、Jiao-Jiao Zhai、Hong-Wei Liu、Qi Cai、Liu-Xin Xu、Wei Wang、Ya-Fei Ji
    DOI:10.1016/j.tet.2012.11.012
    日期:2013.1
    A concise ‘one-pot’ synthesis of a variety of 4-substituted 1,5-diaryl-1H-pyrazole-3-carboxylates has been developed in moderate to good yields with excellent regioselectivity. Less cost lithium tert-butoxide has been identified as a base for sterically hindered Claisen condensation to efficiently generate the labile 3-substituted 4-aryl-2,4-diketoesters. Furthermore, extensive studies lead to a ‘one-pot’
    已经开发了一种简单的“一锅法”合成的各种4-取代的1,5-二芳基-1 H-吡唑-3-羧酸酯,具有中等到良好的产率,具有出色的区域选择性。成本较低的叔丁醇锂已被确定为空间受阻克莱森(Claisen)缩合反应的碱,可有效生成不稳定的3-取代的4-芳基-2,4-二酮酸酯。此外,广泛的研究通过克莱森缩合反应和克诺尔反应相结合而合成“有价值的4-取代的1,5-二芳基-1 H-吡唑-3-羧酸酯”的“一锅法”工艺。
  • Synthesis, spectral studies and tritiation of the cannabinoid antagonist SR141716A
    作者:Herbert H. Seltzman、F. Ivy Carroll、Jason P. Burgess、Christopher D. Wyrick、David F. Burch
    DOI:10.1039/c39950001549
    日期:——
    An efficient synthesis of the cannabinoid antagonist SR141716A is presented and the structure is established by nOe experiments; tritiated SR141716A is synthesized by a novel sequence of metallation–iodination–tritiation and the labelled site is shown by tritium NMR and tritium–hydrogen nOe experiments.
    提出了一种高效合成大麻素拮抗剂SR141716A的方法,并通过nOe实验确定其结构;采用属化-化-氚化的新顺序合成了氚标记的SR141716A,并通过氚核磁共振及氚-氢nOe实验展示了标记部位。
  • PROCESS FOR PREPARATION OF PYRAZOLE DERIVATIVES
    申请人:Shah Darmesh Mahendrabhai
    公开号:US20100190988A1
    公开(公告)日:2010-07-29
    A process for preparation of Pyrazole derivatives adapted for one pot reaction involving the use of a pyclizing agent and involving the step of amidation in the presence of a catalyst. The steps for isolation and purification of found Pyrazole derivatives are also disclosed.
  • US8431609B2
    申请人:——
    公开号:US8431609B2
    公开(公告)日:2013-04-30
  • [EN] AN IMPROVED PROCESS FOR THE PREPARATION OF RIMONABANT<br/>[FR] PROCÉDÉ AMÉLIORÉ DE PRÉPARATION DU RIMONABANT
    申请人:IND SWIFT LAB LTD
    公开号:WO2008062480A2
    公开(公告)日:2008-05-29
    [EN] The present invention relates to an industrially advantageous, eco-friendly process for the re aration of rimonabant of formula-(I), staring from l-(4-chlorophenyl)-propan-l-one in high yields and high purity by using mild reaction conditions and avoiding use of toxic and expensive reagents, as well as stringent reaction conditions. The present invention relates to an isolated impurity of rimonabant, referred to as "Bis impurity" and removal thereof.1 The present invention also relates to novel crystalline form-Ill of rimonabant and processes for its preparation and conversion to form-I of rimonabant.
    [FR] L'invention porte sur un procédé industriellement avantageux, écologique et à fort rendement, de préparation de rimonabant de formule (I) de grande pureté, à partir de l-(4-chlorophényle)-propane-l-one en utilisant des conditions de réaction douces et en évitant l'utilisation de réactifs toxiques et chers, aussi bien que des conditions de réaction contraignantes. L'invention porte également sur l'isolement et l'élimination d'une impureté du rimonabant, dite "impureté Bis ". L'invention porte en outre sur une nouvelle forme cristalline de formule (III) du rimonabant et sur son procédé de préparation et de conversion pour obtenir le rimonabant de formule (I)
查看更多